SELECT B — Selectimmune Pharma AB Income Statement
0.000.00%
HealthcareHighly SpeculativeMicro Cap
- SEK41.38m
- SEK35.54m
Annual income statement for Selectimmune Pharma AB, fiscal year end - June 30th, SEK millions except per share, conversion factor applied.
2018 June 30th | 2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | |
---|---|---|---|---|---|
Period Length: | 16 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | SAS | SAS | SAS | SAS | SAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 0.013 | 3.93 | 8.24 | 12.6 | 14.1 |
Operating Profit | -0.013 | -3.93 | -8.24 | -12.6 | -14.1 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -0.013 | -3.93 | -8.24 | -12.6 | -14.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.013 | -3.93 | -8.24 | -12.6 | -14.1 |
Net Income Before Extraordinary Items | |||||
Net Income | -0.013 | -3.93 | -8.24 | -12.6 | -14.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.013 | -3.93 | -8.24 | -12.6 | -14.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.026 | -0.337 | -0.52 | -0.724 | -0.806 |
Dividends per Share |